PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CRSP vs. NTLA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Performance

CRSP vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%JuneJulyAugustSeptemberOctoberNovember
-14.73%
-45.27%
CRSP
NTLA

Returns By Period

In the year-to-date period, CRSP achieves a -24.44% return, which is significantly higher than NTLA's -53.53% return.


CRSP

YTD

-24.44%

1M

-3.31%

6M

-14.73%

1Y

-30.33%

5Y (annualized)

-6.86%

10Y (annualized)

N/A

NTLA

YTD

-53.53%

1M

-32.78%

6M

-45.27%

1Y

-49.61%

5Y (annualized)

-1.10%

10Y (annualized)

N/A

Fundamentals


CRSPNTLA
Market Cap$4.68B$1.70B
EPS-$2.79-$5.45
PEG Ratio-0.21-0.10
Total Revenue (TTM)$201.62M$43.09M
Gross Profit (TTM)$61.70M$35.51M
EBITDA (TTM)-$317.82M-$521.07M

Key characteristics


CRSPNTLA
Sharpe Ratio-0.38-0.73
Sortino Ratio-0.24-0.91
Omega Ratio0.970.90
Calmar Ratio-0.26-0.49
Martin Ratio-0.60-1.60
Ulcer Index33.67%28.39%
Daily Std Dev51.67%61.60%
Max Drawdown-81.61%-92.10%
Current Drawdown-77.48%-91.98%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.7

The correlation between CRSP and NTLA is 0.67, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Risk-Adjusted Performance

CRSP vs. NTLA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CRSP, currently valued at -0.38, compared to the broader market-4.00-2.000.002.004.00-0.38-0.73
The chart of Sortino ratio for CRSP, currently valued at -0.24, compared to the broader market-4.00-2.000.002.004.00-0.24-0.91
The chart of Omega ratio for CRSP, currently valued at 0.97, compared to the broader market0.501.001.502.000.970.90
The chart of Calmar ratio for CRSP, currently valued at -0.26, compared to the broader market0.002.004.006.00-0.26-0.49
The chart of Martin ratio for CRSP, currently valued at -0.60, compared to the broader market-10.000.0010.0020.0030.00-0.60-1.60
CRSP
NTLA

The current CRSP Sharpe Ratio is -0.38, which is higher than the NTLA Sharpe Ratio of -0.73. The chart below compares the historical Sharpe Ratios of CRSP and NTLA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.40JuneJulyAugustSeptemberOctoberNovember
-0.38
-0.73
CRSP
NTLA

Dividends

CRSP vs. NTLA - Dividend Comparison

Neither CRSP nor NTLA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CRSP vs. NTLA - Drawdown Comparison

The maximum CRSP drawdown since its inception was -81.61%, smaller than the maximum NTLA drawdown of -92.10%. Use the drawdown chart below to compare losses from any high point for CRSP and NTLA. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%-70.00%JuneJulyAugustSeptemberOctoberNovember
-77.48%
-91.98%
CRSP
NTLA

Volatility

CRSP vs. NTLA - Volatility Comparison

The current volatility for CRISPR Therapeutics AG (CRSP) is 17.94%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 29.23%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%JuneJulyAugustSeptemberOctoberNovember
17.94%
29.23%
CRSP
NTLA

Financials

CRSP vs. NTLA - Financials Comparison

This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items